CompletedPhase 1NCT00006185
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
Studying Lipodystrophy due to peptidic growth factors deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Principal Investigator
- Dr.Marie GelatoSUNY at Stony Brook
- Intervention
- Avandia administration for 6-12 weeks(drug)
- Eligibility
- 18-55 years · All sexes
- Timeline
- 1999 – 2003
Study locations (1)
- University Hospital at Stony Brook New York, Stony Brook, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006185 on ClinicalTrials.govOther trials for Lipodystrophy due to peptidic growth factors deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07091734Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024University of Michigan
- RECRUITINGNCT02325674MEASuRE: Metreleptin Effectiveness And Safety RegistryAmryt Pharma
See all trials for Lipodystrophy due to peptidic growth factors deficiency →